XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.23.3

REVENUE (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table summarizes the disaggregation of revenue by nature:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in millions | 2023 |  | 2022 |  | 2023 |  | 2022
Net product sales | $ | 10,645 |  |  | $ | 10,813 |  |  | $ | 32,610 |  |  | $ | 33,606 |
Alliance revenues | 138 |  |  | 173 |  |  | 461 |  |  | 560 |
Other revenues | 183 |  |  | 232 |  |  | 458 |  |  | 587 |
Total Revenues | $ | 10,966 |  |  | $ | 11,218 |  |  | $ | 33,529 |  |  | $ | 34,753 |
Revenue Recognition Gross-To-Net Adjustments | The following table summarizes GTN adjustments:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in millions | 2023 |  | 2022 |  | 2023 |  | 2022
Gross product sales | $ | 18,648 |  |  | $ | 17,606 |  |  | $ | 54,047 |  |  | $ | 51,555 |
GTN adjustments (a) |  |  |  |  |  |  |
Charge-backs and cash discounts | (2,373) |  |  | (1,907) |  |  | (6,743) |  |  | (5,420) |
Medicaid and Medicare rebates | (3,730) |  |  | (3,295) |  |  | (9,355) |  |  | (8,003) |
Other rebates, returns, discounts and adjustments | (1,900) |  |  | (1,591) |  |  | (5,339) |  |  | (4,526) |
Total GTN adjustments | (8,003) |  |  | (6,793) |  |  | (21,437) |  |  | (17,949) |
Net product sales | $ | 10,645 |  |  | $ | 10,813 |  |  | $ | 32,610 |  |  | $ | 33,606 |
(a) Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $18 million and $116 million for the three and nine months ended September 30, 2023 and $10 million and $207 million for the three and nine months ended September 30, 2022, respectively.
Revenue from External Customers by Products and Services | The following table summarizes the disaggregation of revenue by product and region:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
Dollars in millions | 2023 |  | 2022 |  | 2023 |  | 2022
In-Line Products |  |  |  |  |  |  |
Eliquis | $ | 2,705 |  |  | $ | 2,655 |  |  | 9,332 |  |  | 9,101 |
Opdivo | 2,275 |  |  | 2,047 |  |  | 6,622 |  |  | 6,033 |
Pomalyst/Imnovid | 872 |  |  | 886 |  |  | 2,551 |  |  | 2,620 |
Orencia | 925 |  |  | 883 |  |  | 2,616 |  |  | 2,551 |
Sprycel | 517 |  |  | 560 |  |  | 1,404 |  |  | 1,587 |
Yervoy | 579 |  |  | 523 |  |  | 1,672 |  |  | 1,563 |
Mature and other products | 476 |  |  | 514 |  |  | 1,415 |  |  | 1,563 |
Total In-Line Products | 8,349 |  |  | 8,068 |  |  | 25,612 |  |  | 25,018 |
New Product Portfolio |  |  |  |  |  |  |
Reblozyl | 248 |  |  | 190 |  |  | 688 |  |  | 518 |
Abecma | 93 |  |  | 107 |  |  | 372 |  |  | 263 |
Opdualag | 166 |  |  | 84 |  |  | 437 |  |  | 148 |
Zeposia | 123 |  |  | 69 |  |  | 301 |  |  | 171 |
Breyanzi | 92 |  |  | 44 |  |  | 263 |  |  | 127 |
Onureg | 43 |  |  | 32 |  |  | 121 |  |  | 87 |
Inrebic | 29 |  |  | 21 |  |  | 81 |  |  | 62 |
Camzyos | 68 |  |  | 5 |  |  | 143 |  |  | 8 |
Sotyktu | 66 |  |  | 1 |  |  | 107 |  |  | 1 |
Total New Product Portfolio | 928 |  |  | 553 |  |  | 2,513 |  |  | 1,385 |
Total In-Line Products and New Product Portfolio | 9,277 |  |  | 8,621 |  |  | 28,125 |  |  | 26,403 |
Recent LOE Products(a) |  |  |  |  |  |  |
Revlimid | 1,429 |  |  | 2,420 |  |  | 4,647 |  |  | 7,718 |
Abraxane | 260 |  |  | 177 |  |  | 757 |  |  | 632 |
Total Recent LOE Products | 1,689 |  |  | 2,597 |  |  | 5,404 |  |  | 8,350 |
Total revenues | $ | 10,966 |  |  | $ | 11,218 |  |  | $ | 33,529 |  |  | $ | 34,753 |
United States | $ | 7,628 |  |  | $ | 7,941 |  |  | $ | 23,552 |  |  | $ | 23,903 |
International | 3,153 |  |  | 3,062 |  |  | 9,462 |  |  | 10,216 |
Other(b) | 185 |  |  | 215 |  |  | 515 |  |  | 634 |
Total revenues | $ | 10,966 |  |  | $ | 11,218 |  |  | $ | 33,529 |  |  | $ | 34,753 |
(a) Recent LOE Products include products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity. (b) Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.

X
- Definition Reconciliation of Gross Product Sales to Net Product Sales [Table Text Block] + References No definition available. + Details
Name: | bmy_ReconciliationofGrossProductSalestoNetProductSalesTableTextBlock
Namespace Prefix: | bmy_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration